Recombinant proteins play an important role in medicine and have diverse applications in industrial biotechnology. Lactoglobulin has shown great potential for use in targeted drug delivery and body fluid detoxification because of its ability to bind a variety of molecules. In order to modify the biophysical properties of β-lactoglobulin, a series of single-site mutations were designed using a structure-based approach. A 3-dimensional structure alignment of homologous molecules led to the design of nine β-lactoglobulin variants with mutations introduced in the binding pocket region. Seven stable and correctly folded variants (L39Y, I56F, L58F, V92F, V92Y, F105L, M107L) were thoroughly characterized by fluorescence, circular dichroism, isothermal titration calorimetry, size-exclusion chromatography, and X-ray structural investigations. The effects of the amino acid substitutions were observed as slight rearrangements of the binding pocket geometry, but they also significantly influenced the global properties of the protein. Most of the mutations increased the thermal/chemical stability without altering the dimerization constant or pH-dependent conformational behavior. The crystal structures reveal that the I56F and F105L mutations reduced the depth of the binding pocket, which is advantageous since it can reduce the affinity to endogenous fatty acids. The F105L mutant created a unique binding mode for a fatty acid, supporting the idea that lactoglobulin can be altered to bind unique molecules. Selected variants possessing a unique combination of their individual properties can be used for further, more advanced mutagenesis, and the presented results support further research using β-lactoglobulin as a therapeutic delivery agent or a blood detoxifying molecule. BACKGROUND While there is a known association between low vitamin D levels and increased chronic pain in patients with Sickle Cell Disease (SCD), there are no reported studies evaluating the relationship of vitamin D levels and hospitalization outcomes in this population. The aim of this study was to assess this relationship with hospitalization outcomes defined as the number of emergency room (ER) visits, hospital admissions for pain crisis, and length of hospital stay. DESIGN A retrospective chart review of all pediatric patients with SCD (1-21&nbsp;years old) was performed from January 2015 to January 2016 in an urban-based hospital setting (n&nbsp;=&nbsp;134). Those with at least one reported Vitamin D level who maintained follow up during the time studied were enrolled (n&nbsp;=&nbsp;90). Patient hospitalizations rates were compared between vitamin D deficiency (20&nbsp;ng/ml). RESULTS Patients with both SCD and vitamin D deficiency were more likely to have at least one Emergency Room visit (p&nbsp; less then &nbsp;0.01), at least one admission for pain crisis (p&nbsp; less then &nbsp;0.01), and a longer length of admission (p&nbsp; less then &nbsp;0.0001) when compared to patients with SCD and sufficient vitamin D levels. CONCLUSION There is a significant association between vitamin D levels of less then 20&nbsp;ng/ml and the number of ER visits, hospital admissions for pain crisis, and length of stay in patients with SCD. Further research is required to assess if correcting vitamin D levels may improve hospitalization outcomes in this population. OBJECTIVE To comprehensively compare the vision improvement rate in patients with traumatic optic neuropathy with different surgical timing and other different preoperative conditions. METHODS PubMed, Embase, and Medline-Ovid were searched to identify studies. We performed subgroup analyses for differences in the surgical timing, surgical approach, optic canal fractures, state of consciousness after trauma, time of visual loss development, incision of the optic nerve sheath and treatment methods. RESULTS A total of 74 studies involving 6084 patients were included in the final analysis. In the groups of patients with early (?3 days), middle (4-7 days) and late (&gt;7 days) surgical interventions, 58.4%, 53.2% and 45.4% demonstrated visual improvements, respectively. The results of the statistical analysis revealed that patients with early surgical intervention had a higher improvement rate than patients with late surgical intervention (p=0.00953). The improvement rate was significantly lower for patients who presented with no light perception before surgery than for patients whose vision was better than no light perception (RR=0.498; 95% CI=0.443-0.561; p=0.001) and lower for patients with immediate visual loss after trauma than for those with secondary visual loss (RR=0.639; 95% CI=0.498-0.819; p=0.001). CONCLUSIONS We recommend that patients seek medical treatment as soon as possible after traumatic optic nerve injury, and patients with secondary injuries can have a good recovery effect while still living with light perception or more. The option of treatment and whether to incise the optic nerve sheath still remains controversial. Neuromodulation is recommended for patients with refractory tuberous sclerosis related epilepsy (TRE) who are unable to localize epileptogenic nodules after comprehensive preoperative evaluation or for patients and families who do not agree to resection. We report a patient with refractory TRE who received deep brain stimulation of anterior thalamic nucleus (ANT-DBS) and achieved satisfactory response. To our knowledge, this is the first case of TRE being treated with ANT-DBS. A 22-year-old male was admitted to hospital for refractory TRE seeking surgical treatment. https://www.selleckchem.com/products/atn-161.html Seizures were mainly manifested by deep temporal and frontal lobe epilepsy that are suspected to originate in the limbic system. Magnetic resonance imaging revealed extensive potentially epileptogenic nodules in the brain lacking significant nodules. Scalp electroencephalogram showed a comprehensive, bilateral synchronous low voltage rapid rhythm, unable to localize seizure origin. We performed bilateral ANT-DBS according to the preoperative evaluation, and the frequency and intensity of seizures was significantly reduced after the 15-months follow-up (P＜0.05, Student t-test). Our case extends the therapeutic indications of ANT-DBS to a certain extent, providing a neuromodulation alternative to VNS for TRE who are unsuitable candidates or refuse for resection.